Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 3:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 639 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Relative Bioavailability Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol

NCT04600505
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Treatment A, Treatment B, Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2023 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison Of Two Tablet Formulations Of SB-568859

NCT00470145
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB-568859
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce

NCT00863915
View directory record Official record
Conditions
Healthy
Interventions
Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 26, 2026, 3:43 PM EDT
Not listed Phase 1 Interventional

A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets

NCT01898676
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex Sodium Extended-release 250mg, DEPAKOTE 250mg
Drug
Lead sponsor
Vince & Associates Clinical Research, Inc.
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2013 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult Participants

NCT06571266
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Anaheim, California • Los Alamitos, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

NCT03397329
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-348 Sequence A, AG-348 Sequence B
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 12, 2018 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional

A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies

NCT01725100
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212B (Standard DMSO content), GSK1120212B (Lower DMSO content)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Sarasota, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions

NCT00990301
View directory record Official record
Conditions
Healthy
Interventions
Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc., Uniretic® 15mg/25mg Tablets
Drug
Lead sponsor
Paddock Laboratories, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

NCT05767905
View directory record Official record
Conditions
Healthy
Interventions
PF-06821497 Treatment A, PF-06821497 Treatment B, PF-06821497 Treatment C, PF-06821497 Treatment D, PF-06821497 Treatment E, PF-06821497 Treatment F
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions

NCT00779233
View directory record Official record
Conditions
Healthy
Interventions
Zidovudine tablets 300 mg
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 24, 2008 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Ropinirole 0.25 mg Tablets Under Fasting Conditions

NCT00829504
View directory record Official record
Conditions
Healthy
Interventions
Ropinirole HCl 0.25 mg Tablets, Requip® 0.25 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2009 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Fasting Conditions

NCT00829426
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 26, 2026, 3:43 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability and Food-Effect Study of GSK3640254 Tablet and Capsule Formulations in Healthy Participants

NCT04128293
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254 Tablet, GSK3640254 Capsule
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.

NCT07545226
View directory record Official record
Conditions
Healthy Participants
Interventions
Evolocumab Drug Substance A (Test), Evolocumab Drug Substance B (Reference)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
405 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
4
States / cities
Anaheim, California • South Miami, Florida • Springfield, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 26, 2026, 3:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

NCT07540338
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
AL001, Lithium carbonate
Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

NCT00867685
View directory record Official record
Conditions
Healthy
Interventions
AZD2624
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

NCT06577259
View directory record Official record
Conditions
Healthy Participants
Interventions
BMS-986435
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

NCT02461160
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of 60 mg Nifedipine Extended Release Tablets Under Fasting Conditions

NCT00865891
View directory record Official record
Conditions
Healthy
Interventions
Nifedipine Extended Release tablets 60 mg, single dose, ADALAT® CC Extended Release Tablets 60 mg
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Oxandrolone in Healthy Adults: A Relative Bioavailability Study

NCT03218631
View directory record Official record
Conditions
Bioavailability
Interventions
Oxandrin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

NCT06895356
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Tavapadon
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Oct 26, 2026, 3:43 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

NCT03058822
View directory record Official record
Conditions
Healthy
Interventions
BMS-931699
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

NCT05446142
View directory record Official record
Conditions
Healthy
Interventions
Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 26, 2026, 3:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Zaleplon 10 mg Capsules Under Non-Fasting Conditions

NCT00829868
View directory record Official record
Conditions
Healthy
Interventions
Zaleplon 10 mg Capsules, SONATA® 10 mg capsules
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 26, 2026, 3:43 PM EDT